What are the latest anamorelin clinical trial results and FDA status for cancer cachexia in the US as of 2026?

What Anamorelin Is and Why It Matters for Cancer Patients

Anamorelin is an oral ghrelin receptor agonist developed to address cancer-related anorexia and cachexia, a wasting syndrome that affects a substantial proportion of patients with advanced malignancies. The drug works by mimicking the action of ghrelin, a naturally occurring hormone that stimulates appetite, promotes fat accumulation, and supports lean body mass retention. In the United States, anamorelin has been the subject of multiple clinical trials aimed at demonstrating its efficacy and safety for this specific indication, and its regulatory path has drawn sustained attention from oncologists, patients, and pharmaceutical stakeholders. As of mid-2026, the drug remains under active regulatory review, with new data from ongoing and recently completed trials shaping expectations about its eventual availability. Understanding the current state of anamorelin clinical trials in the US requires a close look at the evidence base, the regulatory timeline, and the practical considerations for patients and clinicians who are weighing treatment options.

Also worth reading: How Should Hospitals Measure AI ROI Across Clinical, Operational, and Financial Results in 2026? · Where should clinical AI autonomy limits be drawn to balance innovation and patient safety? · What Is the Real ROI of AI Clinical Documentation Review for Healthcare Organizations?

The Clinical Evidence Base Through 2026

The evidence supporting anamorelin for cancer-related cachexia has been built through a series of randomized, double-blind, placebo-controlled trials conducted in both Japan and the United States. The pivotal ROMANA 1 and ROMANA 2 studies, which enrolled patients with non-small cell lung cancer and other solid tumors, demonstrated that anamorelin at doses of 50 mg or 100 mg once daily produced statistically significant increases in lean body mass compared with placebo over a 12-week treatment period. These trials also showed improvements in handgrip strength, a functional measure that correlates with physical performance and quality of life in cachectic patients. A systematic review and meta-analysis published on nature.com, which synthesized data from multiple anamorelin trials, confirmed that the drug consistently increased body weight and lean mass across study populations, though the magnitude of effect varied depending on tumor type, baseline nutritional status, and concurrent anticancer therapies. By early 2026, additional analyses of long-term extension data from these trials had been presented at major oncology conferences, providing further insight into the durability of anamorelin's effects on body composition. The safety profile observed across these studies has been generally manageable, with the most common adverse events including mild to moderate nausea, hyperglycemia, and transient elevations in liver enzymes, which are consistent with the known pharmacology of ghrelin receptor activation.

FDA Regulatory Pathway and Current Status in 2026

Anamorelin was originally approved in Japan in 2021 under the brand name Anamorelin, making it the first ghrelin receptor agonist to reach the market for cancer cachexia. In the United States, the drug's development path has been more complex, requiring the submission of a New Drug Application to the FDA with robust evidence of efficacy and safety from trials conducted in US populations. The FDA has engaged with the sponsor through multiple pre-submission meetings, and as of August 2026, the agency has not yet issued a final approval decision for anamorelin in the US market. The review process has been shaped by discussions around the appropriate clinical endpoints for a cachexia indication, with the FDA expressing interest in functional outcomes such as handgrip strength and physical performance in addition to weight-based measures. The agency has also requested additional analyses of the safety data, particularly regarding the cardiovascular and metabolic effects observed in some trial participants, including changes in fasting glucose and insulin levels. While the exact timeline for a decision remains uncertain, industry analysts and clinical researchers monitoring anamorelin clinical trials US 2026 expect that the FDA will issue a complete response or an approvable letter if additional data are needed, or move toward a priority review designation if the evidence package is deemed sufficiently compelling. The regulatory uncertainty has created a challenging environment for clinicians and patients who are eager to access the drug outside of clinical trials.

How Anamorelin Compares to Existing and Emerging Cachexia Treatments

When evaluating anamorelin against other interventions for cancer cachexia, it is important to consider the limited number of approved pharmacologic options currently available in the US. Megestrol acetate, a progestational agent, has been used for decades to stimulate appetite in cachectic cancer patients, but its benefits are primarily limited to weight gain that is largely composed of fat rather than lean mass, and it carries risks of thromboembolic events and adrenal suppression. Corticosteroids such as dexamethasone can improve appetite and sense of well-being in the short term but are associated with muscle wasting over prolonged use, making them a suboptimal long-term strategy. In contrast, anamorelin's mechanism of action directly targets the ghrelin pathway, which plays a central role in regulating hunger and energy balance, and clinical trial data suggest that it promotes gains in lean body mass rather than adipose tissue alone. A comparison of the key features of these treatment options highlights the potential advantages and limitations of anamorelin relative to existing therapies. The table below summarizes the most relevant distinctions that clinicians and patients should consider when discussing treatment plans.

This comparison underscores that anamorelin occupies a distinct therapeutic niche, offering a mechanism and a clinical effect profile that differs meaningfully from older agents. However, it is also important to recognize that anamorelin is not a cure for cachexia and that its benefits must be weighed against its cost, its need for daily dosing, and the possibility of adverse effects that may limit tolerability in some patients. The emergence of additional investigational agents targeting different pathways involved in muscle wasting, such as selective androgen receptor modulators and anti-myostatin antibodies, means that anamorelin will face competition in the cachexia treatment space even if it receives FDA approval.

Practical Steps for Patients and Clinicians Considering Anamorelin

For patients with cancer-related cachexia who are interested in anamorelin, the most practical first step is to discuss the current evidence and regulatory status with their oncologist or a palliative care specialist who has experience managing nutritional and metabolic complications of malignancy. Clinicians should review the patient's overall treatment goals, the stage and type of cancer, the degree of weight loss and muscle depletion, and any comorbidities such as diabetes or liver disease that could affect the risk-benefit calculus for anamorelin. In the US, access to anamorelin outside of clinical trials is not yet available, so patients who wish to receive the drug must either participate in a clinical trial or, in some cases, explore expanded access or compassionate use programs if these are offered by the sponsor. Identifying active trials through clinical trial registries such as ClinicalTrials.gov and discussing eligibility criteria with trial coordinators can help patients determine whether participation is feasible given their geographic location, treatment schedule, and health status. For clinicians, staying informed about the latest data from anamorelin clinical trials US 2026 and engaging with professional society guidelines as they are updated will be essential for making timely and evidence-based recommendations. It is also important to set realistic expectations with patients, as anamorelin is not likely to reverse cachexia entirely and should be viewed as one component of a comprehensive management plan that includes nutritional support, physical therapy, and optimization of anticancer therapy.

Common Mistakes and Misconceptions About Anamorelin

One of the most common mistakes surrounding anamorelin is the assumption that any drug promoting weight gain in cachectic patients will automatically improve survival or functional status, when in reality the composition of weight gained and the impact on physical performance are what matter most. Patients and families sometimes conflate anamorelin with appetite stimulants like megestrol or corticosteroids, expecting rapid and dramatic improvements in energy and strength that the drug may not deliver, particularly in patients with advanced disease or significant comorbidities. Another misconception is that because anamorelin has been approved in Japan, it must be safe and effective for all populations, ignoring the fact that regulatory standards, trial populations, and dosing strategies can differ across regions and that US approval requires its own evidence base. Clinicians may also underestimate the importance of monitoring metabolic parameters, including blood glucose and liver function, during anamorelin treatment, which can lead to unrecognized adverse effects if laboratory surveillance is not performed regularly. Finally, there is a tendency to view anamorelin as a standalone solution for cachexia, when the evidence consistently shows that pharmacologic intervention works best when combined with nutritional counseling, resistance exercise, and aggressive management of the underlying cancer and its symptoms.

Cost, Access, and What to Expect in the Near Term

The cost of anamorelin, once it becomes available in the US market, is expected to be substantial, reflecting the pricing models typical of specialty oncology and rare disease drugs, though exact figures will depend on the negotiated prices with payers and the formulary decisions of pharmacy benefit managers. For patients with commercial insurance, Medicare, or Medicaid, coverage will likely require documentation of the cancer diagnosis, evidence of cachexia, and, if the drug is still under regulatory review at the time of launch, participation in a restricted distribution program or prior authorization process. The timeline for availability in the US remains uncertain, with analysts projecting a potential approval decision sometime in late 2026 or early 2027 depending on the FDA's review trajectory and any additional data requests. In the interim, patients who are interested in anamorelin should focus on optimizing their nutritional intake, engaging in supervised physical activity to preserve muscle mass, and maintaining open communication with their care team about emerging treatment options. The broader landscape of cachexia therapeutics is evolving rapidly, and anamorelin represents one of the most promising pharmacologic approaches to address the unmet need for treatments that can meaningfully improve body composition and physical function in cancer patients.

Looking Ahead: The Future of Anamorelin and Cachexia Treatment

The trajectory of anamorelin clinical trials US 2026 reflects a broader shift in oncology toward recognizing cachexia as a treatable condition rather than an inevitable consequence of advanced disease. As more data from long-term extension studies and real-world evidence efforts become available, the understanding of which patient subgroups benefit most from anamorelin will continue to refine, potentially leading to more targeted use of the drug in combination with specific anticancer therapies or in earlier stages of cachexia. The integration of digital health tools and AI-driven monitoring platforms may also enhance the ability to track body composition changes, functional outcomes, and adverse events in patients receiving anamorelin, providing clinicians with richer data to guide treatment decisions. However, significant challenges remain, including the need for standardized diagnostic criteria for cancer cachexia, the development of validated surrogate endpoints that regulators and clinicians can agree on, and the addressing of health equity concerns related to access to expensive new therapies. For healtho.io readers and patients navigating these complexities, the key takeaway is that anamorelin represents a meaningful step forward in the management of cancer cachexia, but it is not a panacea, and its ultimate role in clinical practice will depend on the strength of the evidence, the regulatory decisions that shape its availability, and the willingness of the healthcare system to integrate it into a comprehensive, patient-centered approach to cancer care.